Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 868 | $27.60 | $23,956.80 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 619 | $27.00 | $16,713.00 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:36 UTC |
EVANS GARY CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-21-021528 · doc4.xml · derivative · entry 9 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2029-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Plan vested one (1) year from the December 12, 2019 grant date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:36 UTC |
EVANS GARY CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021528 · doc4.xml · derivative · entry 8 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Plan vested one (1) year from the December 13, 2018 grant date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:36 UTC |
EVANS GARY CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $99.80 | $0.00 |
DisclosureSEC source: 0001209191-21-021528 · doc4.xml · derivative · entry 7 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested six (6) months from the March 15, 2016 grant date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:36 UTC |
EVANS GARY CDirector
|
SaleCommon Stock | 14,768 | $212.00 | $3,130,816.00 |
DisclosureSEC source: 0001209191-21-021528 · doc4.xml · nonDerivative · entry 5 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,099 Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:36 UTC |
EVANS GARY CDirector
|
SaleCommon Stock | 9,732 | $210.00 | $2,043,720.00 |
DisclosureSEC source: 0001209191-21-021528 · doc4.xml · nonDerivative · entry 4 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,867 Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:36 UTC |
EVANS GARY CDirector
|
Exercise / conversionCommon Stock | 18,000 | $3.99 | $71,730.00 |
DisclosureSEC source: 0001209191-21-021528 · doc4.xml · nonDerivative · entry 3 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:36 UTC |
EVANS GARY CDirector
|
Exercise / conversionCommon Stock | 4,500 | $46.00 | $207,000.00 |
DisclosureSEC source: 0001209191-21-021528 · doc4.xml · nonDerivative · entry 2 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:36 UTC |
EVANS GARY CDirector
|
Exercise / conversionCommon Stock | 2,000 | $99.80 | $199,600.00 |
DisclosureSEC source: 0001209191-21-021528 · doc4.xml · nonDerivative · entry 1 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 190 | $168.09 | $31,937.10 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 24 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
Exercise / conversionStock Appreciation Right · Derivative | 383 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · derivative · entry 28 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,884 Underlying: Common Stock · 383 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · kind: The reporting person received 190 shares of common stock upon the net exercise of 383 stock appreciation rights. The reporting person forfeited 14 shares of common stock underlying the stock appreciation rights representing the base value and 179 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 5, 2021 of $174.84. F22 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,083 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · derivative · entry 27 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,584 Underlying: Common Stock · 2,083 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F21 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 521 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · derivative · entry 26 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,465 Underlying: Common Stock · 521 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F20 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 417 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · derivative · entry 25 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,175 Underlying: Common Stock · 417 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F19 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 179 | $174.84 | $31,296.36 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 23 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · kind: The reporting person received 190 shares of common stock upon the net exercise of 383 stock appreciation rights. The reporting person forfeited 14 shares of common stock underlying the stock appreciation rights representing the base value and 179 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 5, 2021 of $174.84. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
Disposition to issuerCommon Stock | 14 | $174.84 | $2,447.76 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 22 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · kind: The reporting person received 190 shares of common stock upon the net exercise of 383 stock appreciation rights. The reporting person forfeited 14 shares of common stock underlying the stock appreciation rights representing the base value and 179 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 5, 2021 of $174.84. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 383 | $5.95 | $2,278.85 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 21 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · kind: The reporting person received 190 shares of common stock upon the net exercise of 383 stock appreciation rights. The reporting person forfeited 14 shares of common stock underlying the stock appreciation rights representing the base value and 179 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 5, 2021 of $174.84. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 12 | $175.16 | $2,101.92 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 20 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 186 | $173.54 | $32,277.96 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 19 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.82 to $173.79, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 203 | $172.24 | $34,964.21 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 18 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.81 to $172.61, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 314 | $171.23 | $53,767.19 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 17 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.76 to $171.57, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 336 | $170.25 | $57,205.65 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 16 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,002 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.75 to $170.74, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 91 | $168.89 | $15,369.19 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 15 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,338 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.75 to $169.61, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 167 | $167.73 | $28,010.83 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 14 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,429 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.29 to $167.87, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 263 | $166.48 | $43,783.90 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 13 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,596 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.21 to $166.98, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 162 | $163.53 | $26,491.76 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 12 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,859 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.12 to $163.94, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 172 | $160.82 | $27,661.42 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 11 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,021 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.59 to $161.18, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 101 | $159.02 | $16,061.37 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 10 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,193 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.50 to $159.35, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 160 | $157.08 | $25,132.80 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 9 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,294 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.46 to $157.43, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 135 | $155.64 | $21,011.44 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 8 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,454 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.99 to $155.87, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 185 | $154.00 | $28,490.44 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 7 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,589 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.88 to $154.72, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 312 | $153.24 | $47,812.32 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 6 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,774 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.785 to $153.60, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 150 | $152.39 | $22,859.18 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 5 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,086 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.73 to $152.60, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
SaleCommon Stock | 72 | $150.31 | $10,822.44 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 4 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,236 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.31 to $150.32, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 2,083 | $5.95 | $12,393.85 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 3 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 521 | $46.00 | $23,966.00 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:38 UTC |
Trizzino JohnEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 417 | $27.60 | $11,509.20 |
DisclosureSEC source: 0001209191-21-019275 · doc4.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,063 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · derivative · entry 19 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,938 Underlying: Common Stock · 2,063 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 416 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · derivative · entry 18 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,175 Underlying: Common Stock · 416 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 416 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · derivative · entry 17 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,176 Underlying: Common Stock · 416 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 12 | $232.35 | $2,788.20 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · nonDerivative · entry 16 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 59 | $231.40 | $13,652.89 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · nonDerivative · entry 15 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.18 to $231.54, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 38 | $230.04 | $8,741.68 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · nonDerivative · entry 14 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.91 to $230.65, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 369 | $228.64 | $84,367.61 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · nonDerivative · entry 13 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.29 to $229.245, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 569 | $227.82 | $129,628.16 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · nonDerivative · entry 12 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.25 to $228.23, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 538 | $226.59 | $121,904.56 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · nonDerivative · entry 11 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,322 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $226.11 to $227.10, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 248 | $225.45 | $55,912.64 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · nonDerivative · entry 10 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,860 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.10 to $226.09, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 120 | $224.93 | $26,991.17 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · nonDerivative · entry 9 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,108 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.10 to $225.09, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:37 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 188 | $223.48 | $42,013.85 |
DisclosureSEC source: 0001209191-21-016342 · doc4.xml · nonDerivative · entry 8 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.90, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.